NASDAQ:JUNS - Nasdaq - US48208B2034 - Common Stock - Currency: USD
0.7
+0.01 (+2.19%)
The current stock price of JUNS is 0.7 USD. In the past month the price decreased by -47.05%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 70.39 | 868.64B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.81 | 397.52B | ||
JNJ | JOHNSON & JOHNSON | 16.32 | 392.63B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.92 | 234.20B | ||
MRK | MERCK & CO. INC. | 11.7 | 226.10B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.6 | 213.35B | ||
PFE | PFIZER INC | 8.5 | 149.72B | ||
SNY | SANOFI-ADR | 13.67 | 137.77B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 50.33 | 116.38B | ||
GSK | GSK PLC-SPON ADR | 7.94 | 76.32B | ||
ZTS | ZOETIS INC | 27.87 | 74.44B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.59 | 45.46B |
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. The company has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
JUPITER NEUROSCIENCES INC
1001 North US HWY 1, Suite 504
Palm Beach Gardens FLORIDA US
Employees: 4
Company Website: https://jupiterneurosciences.com/
Phone: 15614066154
The current stock price of JUNS is 0.7 USD. The price increased by 2.19% in the last trading session.
The exchange symbol of JUPITER NEUROSCIENCES INC is JUNS and it is listed on the Nasdaq exchange.
JUNS stock is listed on the Nasdaq exchange.
7 analysts have analysed JUNS and the average price target is 30.6 USD. This implies a price increase of 4271.43% is expected in the next year compared to the current price of 0.7. Check the JUPITER NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalization of 23.17M USD. This makes JUNS a Nano Cap stock.
JUPITER NEUROSCIENCES INC (JUNS) currently has 4 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
JUNS does not pay a dividend.
JUPITER NEUROSCIENCES INC (JUNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).
The outstanding short interest for JUPITER NEUROSCIENCES INC (JUNS) is 0.86% of its float. Check the ownership tab for more information on the JUNS short interest.
Over the last trailing twelve months JUNS reported a non-GAAP Earnings per Share(EPS) of -0.15.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -5588.43% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to JUNS. The Buy consensus is the average rating of analysts ratings from 7 analysts.